25 July  2019  
EMA/C HMP/409666/2019   
C ommittee for Medicinal  Products for Human  Use (C HMP) 
Summary of opinion1  (post authorisation) 
Zerbaxa 
ceftolozane / tazobactam 
On 25 July 2019, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Zerbaxa. The 
marketing authorisation holder for this medicinal product is Merck Sharp & Dohme B.V. 
The CHMP adopted a new indication as follows:2 
“Zerbaxa is indicated for the treatment of the following infections in adults (see section 5.1): 
•  Complicated intra-abdominal infections (see section 4.4); 
•  Acute pyelonephritis; 
•  Complicated urinary tract infections (see section 4.4); 
•  Hospital-acquired  pneumonia  (HAP), including  ventilator-associated  pneumonia  (VAP). 
Consideration should be given to official guidance on the appropriate use of antibacterial agents.” 
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without pre judice to the C ommission de cision, which will normally be issued 67 days 
from  adoption of the opinion 
2 Ne w te x t in bold 
Of f icial address  D omenic o Scarlattilaan 6   ●  1 0 83 H S A msterdam  ●  T he N etherlands 
A ddress f or visits and deliveries  Refer to www.ema.europa.eu/how- to- find- us  
Send us a question  G o to www.ema.europa.eu/c ontac t   Telephone +3 1  (0 )8 8  7 81 6 000 
An agency  of  the European  Union    
© E uropean M edic ines  A genc y, 2 0 1 9 . Reproduc tion is  authoris ed provided the s ourc e is  ac knowledged. 
 
  
 
 
 
  
 
                                                 
